Skip to main content

AC Immune SA (ACIU)

NASDAQ: ACIU · IEX Real-Time Price · USD
5.17 -0.18 (-3.36%)
Nov 26, 2021 1:00 PM EST - Market closed
Market Cap375.61M
Revenue (ttm)17.54M
Net Income (ttm)-70.36M
Shares Out72.65M
EPS (ttm)-1.06
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume467,256
Open5.79
Previous Close5.35
Day's Range5.05 - 5.41
52-Week Range4.81 - 12.61
Beta0.77
AnalystsStrong Buy
Price Target15.18 (+193.5%)
Earnings DateNov 12, 2021

About ACIU

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Ph...

IndustryBiotechnology
IPO DateSep 23, 2016
CEOAndrea Pfeifer
Employees125
Stock ExchangeNASDAQ
Ticker SymbolACIU
Full Company Profile

Financial Performance

Financial numbers in millions CHFFinancial Statements

Analyst Forecast

According to 3 analysts, the average rating for AC Immune stock is "Strong Buy." The 12-month stock price forecast is 15.18, which is an increase of 193.55% from the latest price.

Price Target
$15.18
(193.55% upside)
Analyst Consensus: Strong Buy

News

AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer's Vaccine Generates a Po...

Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment

2 weeks ago - GlobeNewsWire

AC Immune Announces Late-Breaker Presentation by Genentech at CTAD on Phase 2 Lauriet Study of Semorinemab in Mild-to...

Analysis of the broader mITT population is consistent with the previously reported success in meeting one of the two co-primary endpoints (ADAS-Cog11) with statistically significant reduction in the rat...

2 weeks ago - GlobeNewsWire

AC Immune (ACIU) Reports Q3 Loss, Misses Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of 17.24% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

AC Immune Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Announced the first positive cognitive results for a Tau-targeting monoclonal antibody in mild-to-moderate Alzheimer's disease

2 weeks ago - GlobeNewsWire

Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago - Zacks Investment Research

AC Immune Extends Research Collaboration with University of Pennsylvania Focusing on the Pathogenic Protein TDP-43, a...

LAUSANNE, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases,...

3 weeks ago - GlobeNewsWire

New Data on AC Immune's Abeta and pTau Clinical Programs in Alzheimer's Disease To Be Presented at CTAD 2021

LAUSANNE, Switzerland, Nov. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases,  today anno...

3 weeks ago - GlobeNewsWire

AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof.

Dr. Shaw is a pharmaceutical industry expert who has been involved in advancing more than 15 therapeutic products from first-in-human studies through commercialization

4 weeks ago - GlobeNewsWire

AC Immune to Present at the Jefferies London Healthcare Conference

LAUSANNE, Switzerland, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today annou...

1 month ago - GlobeNewsWire

Alzheimer's Drug for Roche Partner AC Immune Shows Promise

The ardor for shares of AC Immune SA ( ACIU , Financial) has cooled considerably since the company's Aug. 31 announcement of somewhat promising study results for its Alzheimer's drug. The Swiss biotech'...

2 months ago - GuruFocus

AC Immune CEO Andrea Pfeifer Receives First SEF.WomenAward for CEO of the Year

LAUSANNE, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases...

2 months ago - GlobeNewsWire

AC Immune to Participate in Upcoming Virtual Investor Conferences in September

LAUSANNE, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today anno...

2 months ago - GlobeNewsWire

AC Immune's (ACIU) Stock Up Despite Mixed Data From AD Study

AC Immune's (ACIU) candidate for mild-to-moderate AD meets one of the two co-primary endpoints. Resultantly, the stock price rises 16%

2 months ago - Zacks Investment Research

What Leerink, Wainwright Have To Say For This Alzheimer's Focused Firm

Earlier today, AC Immune SA (NASDAQ:ACIU) announced semorinemab met one of its co-primary endpoints in a mid-stage Alzheimer's disease trial. SVB Leerink notes that semorinemab data is "good news.

2 months ago - Benzinga

ACIU Stock: The Big Alzheimer's News That Has AC Immune Skyrocketing Today

AC Immune (ACIU) stock is rising higher on Tuesday after revealing positive results from a recent Alzheimer's disease study. The post ACIU Stock: The Big Alzheimer's News That Has AC Immune Skyrocketing...

2 months ago - InvestorPlace

Here's Why AC Immune Stock Is Surging Today

MIxed results for the company's Alzheimer's disease candidate are good enough for the market today.

2 months ago - The Motley Fool

See Why AC Immune Stock Is Trading Higher After Data From Alzheimer's Candidate

AC Immune SA (NASDAQ: ACIU) and its collaborating partner Genentech, part of Roche Holdings AG (OTC: RHHBY), have announced topline data from Phase 2 study evaluating semorinemab in mild-to-moderate Alz...

2 months ago - Benzinga

AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer's Disease

Top-line data from Lauriet Phase 2 trial of semorinemab in mild-to-moderate AD shows a statistically significant reduction on one of two co-primary endpoints, ADAS-Cog11

2 months ago - GlobeNewsWire

AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of -31.82% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Announced strategic acquisition of industry-leading Parkinson's disease vaccine and equity investment led by key investors in Covid-19 vaccine innovator BioNTech SE

3 months ago - GlobeNewsWire

AC Immune Presents Full Phase 1b Results on Anti-Abeta Vaccine and Discusses its First-in-Class Diagnostic for Parkin...

ACI-24 generated an encouraging immune response that correlated with a signal of target engagement in patients with Down syndrome (DS)

3 months ago - GlobeNewsWire

Earnings Preview: AC Immune (ACIU) Q2 Earnings Expected to Decline

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

AC Immune Secures Funding From BioNTech Investors, Buys Parkinson's Vaccine Candidate

AC Immune SA (NASDAQ: ACIU) has gained a multi-million investment from the principal backers of BioNTech SE (NASDAQ: BNTX) while acquiring a possible Parkinson's disease vaccine. It announced a $25 mill...

Other symbols:BNTX
4 months ago - Benzinga

AC Immune acquires AFFiRiS' Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegener...

VIENNA, Austria, July 27, 2021 (GLOBE NEWSWIRE) -- AFFiRiS AG, a clinical-stage biotechnology company that has been engaged in the development of novel disease-modifying Specific Active Immunotherapies ...

4 months ago - GlobeNewsWire

AC Immune Announces Strategic Acquisition of Industry-leading Parkinson's Disease Vaccine Candidate and Equity Invest...

All-stock transaction maintains AC Immune's strong cash position

4 months ago - GlobeNewsWire